Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant abemaciclib plus aromatase inhibitor in HR-positive/HER2-negative breast cancer with persistent Ki-67 >10% after 2 weeks of preoperative endocrine therapy
ChiCTR2400081889Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Rate of PEPI score 0. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400081889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081889.